This Is an Alzheimer's Disease Core Center (ADCC) application from investigators at the University of Kansas (KU). Over the past five years the KU team has developed the infrastructure needed to host an ADCC. Longitudinally characterized Alzheimer's disease (AD) and age-matched control cohorts have been established and these cohorts have supported numerous research projects. Our research cohorts have been characterized neuropsychologically per Uniform Data Set (UDS) guidelines and neuroimaged at a research-dedicated neuroimaging Center. Every step has been planned in conjunction with expert statistical support and database management input. Carefully orchestrated outreach to the lay population and local healthcare professionals has facilitated subject recruitment, retention, and raised awareness of our AD research program throughout the Kansas City (KC) metro area, the 29th largest metro area in the USA. The KU ADCC consists of the five NIA-mandated ADCC cores, a Neuroimaging Core, and a Mitochondrial Genomics and Metabolism Core. This infrastructure helps us pursue our principal aim of effectively and comprehensively supporting AD and AD-related research at KU. To this end KU ADCC services have already invigorated KU's AD research portfolio and we currently maintain a diverse portfolio of supported research projects.
A second aim of the KU ADCC is to provide advanced services that enable and facilitate ground-breaking AD, AD-related, and brain aging metabolism research. Our expertise and the highly integrated, Inter-disciplinary services we provide will help the AD research field define how fitness, metabolism, and mitochondria independently and collectively influence progression and outcome in AD. We are confident that incorporating our expertise within the ADC system will prove both practical and valuable, strengthen the existing ADC system, and advance the AD research field.
With the aging population, age-related disorders such as dementia are rising in prevalence at an unprecedented rate. Promoting and supporting clinical and translational research into neurodegenerative disorders may lead to important prevention and treatment strategies.
|Koppel, Scott J; Swerdlow, Russell H (2018) Neuroketotherapeutics: A modern review of a century-old therapy. Neurochem Int 117:114-125|
|Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021|
|Gallagher, Damien; Kiss, Alex; Lanctot, Krista L et al. (2018) Toward Prevention of Mild Cognitive Impairment in Older Adults With Depression: An Observational Study of Potentially Modifiable Risk Factors. J Clin Psychiatry 80:|
|Lin, Ming; Gong, Pinghua; Yang, Tao et al. (2018) Big Data Analytical Approaches to the NACC Dataset: Aiding Preclinical Trial Enrichment. Alzheimer Dis Assoc Disord 32:18-27|
|Barnes, Josephine; Bartlett, Jonathan W; Wolk, David A et al. (2018) Disease Course Varies According to Age and Symptom Length in Alzheimer's Disease. J Alzheimers Dis 64:631-642|
|Kirson, Noam Y; Scott Andrews, J; Desai, Urvi et al. (2018) Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease. J Alzheimers Dis 61:295-307|
|Swerdlow, Russell H (2018) Mitochondria and Mitochondrial Cascades in Alzheimer's Disease. J Alzheimers Dis 62:1403-1416|
|Adamiak, Marta; Cheng, Guangming; Bobis-Wozowicz, Sylwia et al. (2018) Induced Pluripotent Stem Cell (iPSC)-Derived Extracellular Vesicles Are Safer and More Effective for Cardiac Repair Than iPSCs. Circ Res 122:296-309|
|Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211|
|Menta, Blaise W; Swerdlow, Russell H (2018) An Integrative Overview of Non-Amyloid and Non-Tau Pathologies in Alzheimer's Disease. Neurochem Res :|
Showing the most recent 10 out of 333 publications